tert-Butyl 2-(4-oxopiperidin-1-yl)acetate

Catalog No. :
ACHEWI371
CAS No. :
149554-03-0
Molecular Formula :
C11H19NO3
Molecular Weight :
213.28

IUPAC Name:tert-butyl 2-(4-oxopiperidin-1-yl)acetate

tert-Butyl 2-(4-oxopiperidin-1-yl)acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$83.00Login to see priceIn stockInquiry
5g98%$268.00Login to see priceIn stockInquiry
25g98%$1289.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 2-(4-oxopiperidin-1-yl)acetate
IUPAC Nametert-butyl 2-(4-oxopiperidin-1-yl)acetate
MDL No.MFCD07371646
Molecular FormulaC11H19NO3
Molecular Weight213.28
SMILESO=C(OC(C)(C)C)CN1CCC(CC1)=O
InChI KeySBVOSDPEDKERMR-UHFFFAOYSA-N
Synonymtert-Butyl 2-(4-oxopiperidin-1-yl)acetate;1-(TERT-BUTOXYCARBONYLMETHYL)-4-PIPERIDINONE;tert-Butyl (4-oxopiperidin-1-yl)acetate;2-(4-oxo-1-piperidinyl)acetic acid tert-butyl ester;1-Piperidineacetic acid, 4-oxo-, 1,1-dimethylethyl ester;1,1-Dimethylethyl 4-oxo-1-piperidineacetate;tert-Butyl 2-(4-Oxo-1-piperidyl)acetate
CAS No.149554-03-0
PubChem CID53407149

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACHEWI371 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHEWI371 route product structure diagram
    ACHEWI371149554-03-0 In Stock
Inquiry

2. ACHEWI371 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHEWI371 route product structure diagram
    ACHEWI371149554-03-0 In Stock
Inquiry

Comments (0)